Brief: Hyphens Pharma International Inks Exclusive Licensing Deal Of Ustekinumab Biosimilar

Hyphens Pharma International

14/12/2021 08:18

Dec 14 (Reuters) - Hyphens Pharma International  HYPH.SI :
    * HYPHENS PHARMA HAS INKED EXCLUSIVE LICENSING DEAL OF
USTEKINUMAB
BIOSIMILAR
    * UNIT SIGNED AN EXCLUSIVE LICENSE AND SUPPLY AGREEMENT WITH
DKSH'S SUBSIDIARY FAVOREX
    * AGREEMENT TO COMMERCIALISE USTEKINUMAB BIOSIMILAR PRODUCED
BY
ALVOTECH HF IN SINGAPORE, MALAYSIA, AND PHILIPPINES

Source text for Eikon:  ID:nSN52nxJK 
Further company coverage:  HYPH.SI 

 ((Reuters.Briefs@thomsonreuters.com;))